One of the hallmarks of cancer is the limitless proliferation of cancer cells, which is related to telomerase reactivation. Since most cancer cells express telomerase to bypass the replicative limit imposed by telomere length, development and testing of new compounds that target telomerase expressing cancer cells, not normal cells, is a high-priority avenue for emerging cancer therapies. Our lab works on different approaches for telomerase targeted therapy (e.g. direct telomerase inhibition and telomerase mediated telomere targeting approaches). We evaluate their clinical utility in tissue culture, mouse xenografts, and in clinical trials with both industrial and academic partners.